To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
Languages
Recent
Show all languages
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

Michael Fischbach

From Wikipedia, the free encyclopedia

Michael Fischbach
Born(1980-11-03)November 3, 1980
Alma mater
Scientific career
Institutions
Websitefischbachgroup.org

Michael Andrew Fischbach (born November 3, 1980) is an American chemist, microbiologist, and geneticist. He is an associate professor of Bioengineering and ChEM-H Faculty Fellow at Stanford University[1][2] and a Chan Zuckerberg Biohub Investigator.[3]

YouTube Encyclopedic

  • 1/3
    Views:
    3 979
    490
    3 168
  • Michael Fischbach - Faculty Profile
  • Michael Fischbach - Metabolism, interspecies interactions, and novel approaches to...
  • Gut bacteria and antibiotics: Michael Fischbach looks for answers

Transcription

Hi, I'm Michael Fischbach, I'm a member of the faculty in the Department of Bioengineering and Therapeutic Sciences. I came from Harvard University in Cambridge, Massachusetts, where I got my bachelor's degree and also my Ph.D. My lab research is drugs that are made by bacteria, and we do two different things: one is that we found a way to use bioinformatics - which is really just searching on the computer - to look through the genomes of bacteria for genes that make drugs. And that's been an important advance because what it means is that now we can do the hardest most painstaking part of the drug discovery process on the computer. We're very excited about using that to look through the genomes of all of the bacteria that have been sequenced recently, which is a lot, it's well over 1,000 now and growing rapidly, to find new genes that encode new drugs. Not only is this going to help us find drugs we wouldn't have found otherwise, like antibiotics and anticancer agents, but it's also going to allow us to change their genes around in order to make variance of these drugs, that we otherwise wouldn't have been able to make using just chemistry alone. And that's going to allow us to make better drugs with fewer side effects that are more effective. The other thing that my lab looks at is drugs made by a specific set of bacteria, and that is bacteria that live on and inside of human beings. You might not realize it, there are ten times as many bacteria cells that live on and inside of the human body as there are human cells itself. So when I look at a person, I don't just see a warm, shiny human being, I see bacteria crawling all over you, and are living all on every surface that's exposed and not exposed on your entire body. Now you're lucky that they're there because these bacteria are doing very important things for you: they make your immune system function properly, they help you digest foods, and they produce important chemicals that serve as vitamins for your body. What we think, though, is that they're actually making many more chemicals - I'll even call them "drugs" - than we had formerly realized, and that these drugs do one of two important things: one is that they might affect other bacteria that are living on or inside of you in a way that either changes their function, or changes the composition of the community in which these bacteria live. And if they can do that, then that's going to be an important thing because different people have different kinds of bacteria living inside them, and those changes correlate with diseases like Crohn's Disease and obesity. The second thing that we think that these drugs made by the bacteria living on and inside of you might be doing is to change your chemistry specifically: they might be interacting with you directly. What if a bacterium made a molecule that made you hungry, or not hungry? What if a bacterium made a molecule that made you tired or awake? What if a bacterium made a molecule that made you happy or sad? We're interested in things like that, and even things that might not be quite as flashy as that, but still very important, like what if bacteria are making molecules that change the rate at which stuff moves through your gut? We think bacteria might want to do that, and that they're probably already doing a lot of that. So we're looking for new chemical ways in which bacteria are communicating with, and maybe even subverting or helping, their host, which is us.

Education

Fischbach earned his A.B. in Biochemical Sciences from Harvard College in 2003. During that time (2000-2003), he worked in Jeffrey Settleman's lab at the Massachusetts General Hospital Cancer Center on the biochemistry of oncogenic mutants of the small GTPase Ras.[4] In 2007, he earned his Ph.D. in Chemistry and Chemical Biology from Harvard University, working in Christopher T. Walsh's laboratory at Harvard Medical School on iron acquisition in bacterial pathogens and the biochemistry of natural product biosynthesis.[5][6]

Career

Fischbach was a junior fellow in the Department of Molecular Biology at Massachusetts General Hospital (2007-2009) before joining the faculty of the University of California, San Francisco in 2009. He moved to Stanford University as an associate professor in September 2017. As a Chan Zuckerberg Biohub Investigator, Fischbach is one of eight faculty members across Stanford, UCSF, and the University of California, Berkeley leading the CZ Biohub Microbiome Initiative, launched in 2018, with the goal of understanding how the microbiota can influence human health.[7]

Fischbach is currently a member of the scientific advisory board of NGM Biopharmaceuticals[8] and a co-founder of Revolution Medicines.[9]

Research

Fischbach's lab focuses on discovering and characterizing small molecules from microorganisms, with an emphasis on the human microbiome.[10][11]

Small molecules from the human microbiota

In 2014, Fischbach and his laboratory published a survey of biosynthetic genes in the human microbiome, describing the ability of human-associated microbes to produce thiopeptide antibiotics.[12][13][14][15] The Fischbach lab discovered that the gut commensal Bacteroides fragilis produces the immune modulatory sphingolipid alpha-galactosylceramide,[16] showed that the production of neurotransmitters is common among commensal gut bacteria,[17] and discovered the biosynthetic pathway for a common class of bile acids produced by gut bacteria.[18]

Computational approaches to natural product discovery

Fischbach's lab developed an algorithm, ClusterFinder, that automates the process of identifying biosynthetic genes for small molecules in bacterial genome sequences.[19][20] With Marnix Medema, he co-developed a second algorithm for identifying biosynthetic gene clusters, antiSMASH,[21] with which ClusterFinder has been merged.

Personal life

Fischbach is married to Elizabeth Sattely, Associate Professor of Chemical Engineering at Stanford.[22]

External links

References

  1. ^ "Michael Fischbach's Profile | Stanford Profiles". profiles.stanford.edu. Retrieved 2019-07-12.
  2. ^ "Faculty Fellows | ChEM-H". chemh.stanford.edu. Retrieved 2019-07-12.
  3. ^ "Investigator Program – Chan Zuckerberg Biohub". Retrieved 2019-07-12.
  4. ^ Fischbach MA, Settleman J. Specific biochemical inactivation of oncogenic Ras proteins by nucleoside diphosphate kinase. Cancer Res. 2003 Jul 15;63(14):4089-94. PMID 12874011.
  5. ^ Fischbach MA, Lin H, Liu DR, Walsh CT. In vitro characterization of IroB, a pathogen-associated C-glycosyltransferase. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):571-6. Epub 2004 Dec 14. PMID 15598734; PMC 545562.
  6. ^ Walsh CT, Fischbach MA. Natural products version 2.0: connecting genes to molecules. J Am Chem Soc. 2010 Mar 3;132(8):2469-93. doi:10.1021/ja909118a. PMID 20121095; PMC 2828520.
  7. ^ "Chan Zuckerberg Biohub funds new research efforts, microbiome initiative". News Center. 8 February 2017. Retrieved 2019-07-12.
  8. ^ "Scientific Advisory Board - NGM Bio". www.ngmbio.com. Archived from the original on 2018-07-20. Retrieved 2016-01-07.
  9. ^ "Team - Revolution Medicines". revolutionmedicines.com.
  10. ^ "Fischbach Group - Home". fischbachgroup.org.
  11. ^ Donia MS, Fischbach MA. Small molecules from the human microbiota. Science. 2015 Jul 24;349(6246):1254766. doi:10.1126/science.1254766. Epub 2015 Jul 23. Review. PMID 26206939; PMC 4641445
  12. ^ Donia MS, Cimermancic P, Schulze CJ, Wieland Brown LC, Martin J, Mitreva M, Clardy J, Linington RG, Fischbach MA. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell. 2014 Sep 11;158(6):1402-14. doi:10.1016/j.cell.2014.08.032. PMID 25215495; PMC 4164201.
  13. ^ "Mining for Antibiotics, Right Under Our Noses". The New York Times. 2014-09-11.
  14. ^ Park, Alice (2014-09-12). "DIY Drugs: Antibiotics Could Soon Be Made Out of Your Own Bacteria". Time. Retrieved 2018-04-26.
  15. ^ "Set a thief... Humanity's bacterial companions are a good place to look for new drugs". The Economist. 2014-09-20. Retrieved 2018-04-26.
  16. ^ Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA. Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol. 2013 Jul;11(7):e1001610. doi:10.1371/journal.pbio.1001610. Epub 2013 Jul 16. PMID 23874157; PMC 3712910.
  17. ^ Williams BB, Van Benschoten AH, Cimermancic P, Donia MS, Zimmermann M, Taketani M, Ishihara A, Kashyap PC, Fraser JS, Fischbach MA. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe. 2014 Oct 8;16(4):495-503. doi:10.1016/j.chom.2014.09.001. Epub 2014 Sep 25. PMID 25263219; PMC 4260654.
  18. ^ Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat Chem Biol. 2015 Sep;11(9):685-90. doi:10.1038/nchembio.1864. Epub 2015 Jul 20. PMID 26192599; PMC 4543561.
  19. ^ Cimermancic P, Medema MH, Claesen J, Kurita K, Wieland Brown LC, Mavrommatis K, Pati A, Godfrey PA, Koehrsen M, Clardy J, Birren BW, Takano E, Sali A, Linington RG, Fischbach MA. Insights into secondary metabolism from a global analysis of prokaryotic biosynthetic gene clusters. Cell. 2014 Jul 17;158(2):412-21. doi:10.1016/j.cell.2014.06.034. PMID 25036635; PMC 4123684.
  20. ^ Medema MH, Fischbach MA. Computational approaches to natural product discovery. Nat Chem Biol. 2015 Sep;11(9):639-48. doi:10.1038/nchembio.1884. PMID 26284671.
  21. ^ "antiSMASH bacterial version". antismash.secondarymetabolites.org.
  22. ^ "Elizabeth Sattely's Profile | Stanford Profiles". profiles.stanford.edu. Retrieved 2019-07-12.
This page was last edited on 25 April 2024, at 09:35
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.